UK's BBI and NIST in partnership for gold nanoparticles
This article was originally published in Clinica
Executive Summary
Cardiff, UK-based BBI has been chosen by the US National Institute of Standards and Technology (NIST) to provide gold nanoparticles to make nanoscale reference materials for the evaluation and qualification of methodology and instrument performance. The resulting materials will help diagnostic firms make sure that equipment is performing with the required QC parameters for the measurement and characterisation of quality nanoparticles. The gold nanoparticles are used in membrane-based rapid assays due to their stability and ultra-sensitivity. BBI is currently in the process of being acquired by Inverness Medical Innovations (see Clinica No 1286, p 3).
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.